Biotech News

Artivion Completes Acquisition of Endospan Ltd.

Artivion (AORT)Artivion2026-05-18 11:00 ESTCompany update

ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a pioneer in the endovascular repair of aortic arch disease

Open original release

Related news

AORTArtivion2026-05-07 20:05 EST

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

AORTArtivion2026-04-23 20:15 EST

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results

View all latest news

Artivion

Artivion is a medical device company focused on cardiovascular surgery, aortic repair, and preservation technologies. Its products are used in complex cardiac and vascular procedures.

Recent company news

AORTArtivion2026-05-18 11:00 EST

Artivion Completes Acquisition of Endospan Ltd.

AORTArtivion2026-05-07 20:05 EST

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

AORTArtivion2026-04-23 20:15 EST

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results

AORTArtivion2026-04-07 11:00 EST

Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System

AORTArtivion2026-03-03 21:10 EST

Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Stock data

Close: 26.10 USD
Market cap: 991.26M USD
Exchange: NYSE
Sector: MedTech
Location: United States